Fact based stock research
Jointown Pharmaceutical (SHSE:600998)

Jointown Pharmaceutical stock research in summary

Jointown Pharmaceutical shares have a market-typical stock price level. They show above average growth and are good value, but are riskily financed. We recommend evaluating if the future of the company Jointown Pharmaceutical is typical for this industry which the market average price level of the shares suggests. If you believe that the future of the company is above average, that would be an argument for buying the shares and vice versa.

Latest Obermatt Ranks


Value Rank	57
Growth Rank	62
Safety Rank	44
Combined Rank	38

Country	China
Industry	Health Care Distributors
Index	SSE Composite
Size class	X-Large

April 19, 2019. Stock data may be delayed. Login to get the most recent research.

Google: Jointown Pharmaceutical

News	Videos
Wikipedia about Jointown Pharmaceutical	Management
Employee Satisfaction	Customer Satisfaction

Add to Watchlist

Similar Stocks

All Top 10 Lists

Research History: Jointown Pharmaceutical

RESEARCH HISTORY	2016	2017	2018	2019
VALUE
VALUE	52	52	74	57
GROWTH
GROWTH	80	93	46	62
SAFETY
SAFETY	58	58	62	44
COMBINED
COMBINED	80	80	69	38

Last update of Combined Rank: 19-Apr-2019. Stock research history is based on the Obermatt Method. The higher the rank, the better Jointown Pharmaceutical is in the corresponding investment strategy.

Value Metrics in Detail

VALUE METRICS	2016	2017	2018	2019
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S)	87	87	86	90
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E)	35	35	54	53
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book)	64	60	68	73
DIVIDEND YIELD
DIVIDEND YIELD	1	1	42	1
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE	52	52	74	57

Last update of Value Rank: 19-Apr-2019. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Jointown Pharmaceutical; except for dividend yield where the rank is higher, the higher the yield.

Growth Metrics in Detail

GROWTH METRICS	2016	2017	2018	2019
REVENUE GROWTH
REVENUE GROWTH	89	93	42	78
PROFIT GROWTH
PROFIT GROWTH	63	63	80	60
STOCK RETURNS
STOCK RETURNS	51	60	26	28
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH	80	93	46	62

Financial reporting date of Growth Rank: 30-Sep-2018. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Jointown Pharmaceutical.

Safety Metrics in Detail

SAFETY METRICS	2016	2017	2018	2019
LEVERAGE
LEVERAGE	43	30	38	27
REFINANCING
REFINANCING	95	87	96	96
LIQUIDITY
LIQUIDITY	28	13	38	24
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY	58	58	62	44

Financial reporting date of Safety Rank: 30-Sep-2018. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Jointown Pharmaceutical and the more cash is available to service its debt.

Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Jointown Pharmaceutical from April 19, 2019.

We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.